ENTRY       D11079                      Drug
NAME        Satralizumab (USAN/INN);
            Satralizumab (genetical recombination) (JAN);
            satralizumab-mwge;
            Enspryng (TN)
PRODUCT     ENSPRYNG (Genentech)
FORMULA     C6340H9776N1684O2022S46
EXACT_MASS  143326.1068
MOL_WEIGHT  143414.519
SEQUENCE    (Heavy chain)
            QVQLQESGPG LVKPSETLSL TCAVSGHSIS HDHAWSWVRQ PPGEGLEWIG FISYSGITNY
            NPSLQGRVTI SRDNSKNTLY LQMNSLRAED TAVYYCARSL ARTTAMDYWG EGTLVTVSSA
            STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
            LYSLSSVVTV PSSNFGTQTY TCNVDHKPSN TKVDKTVERK SCVECPPCPA PPVAGPSVFL
            FPPKPKDTLM ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV
            VSVLTVVHQD WLNGKEYKCK VSNKGLPAPI EKTISKTKGQ PREPQVYTLP PSQEEMTKNQ
            VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG SFFLYSKLTV DKSRWQEGNV
            FSCSVMHEAL HAHYTQKSLS LSP
            (heavy chain)
            QVQLQESGPG LVKPSETLSL TCAVSGHSIS HDHAWSWVRQ PPGEGLEWIG FISYSGITNY
            NPSLQGRVTI SRDNSKNTLY LQMNSLRAED TAVYYCARSL ARTTAMDYWG EGTLVTVSSA
            STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
            LYSLSSVVTV PSSNFGTQTY TCNVDHKPSN TKVDKTVERK SCVECPPCPA PPVAGPSVFL
            FPPKPKDTLM ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV
            VSVLTVVHQD WLNGKEYKCK VSNKGLPAPI EKTISKTKGQ PREPQVYTLP PSQEEMTKNQ
            VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG SFFLYSKLTV DKSRWQEGNV
            FSCSVMHEAL HAHYTQKSLS LSP
            (Light chain)
            DIQMTQSPSS LSASVGDSVT ITCQASTDIS SHLNWYQQKP GKAPELLIYY GSHLLSGVPS
            RFSGSGSGTD FTFTISSLEA EDAATYYCGQ GNRLPYTFGQ GTKVEIERTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (light chain)
            DIQMTQSPSS LSASVGDSVT ITCQASTDIS SHLNWYQQKP GKAPELLIYY GSHLLSGVPS
            RFSGSGSGTD FTFTISSLEA EDAATYYCGQ GNRLPYTFGQ GTKVEIERTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H96, H146-H202, H222-L214, H225-h225, H228-h228, H259-H319, H365-H423, h22-h96, h146-l202, h222-l214, h259-h319, h365-h423, L23-L88, L134-L194, l23-l88, l134-l194)
  TYPE      Peptide
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
REMARK      Therapeutic category: 6399
            ATC code: L04AC19
            Product: D11079<JP/US>
EFFICACY    Anti-inflammatory, Immunosuppressant, Anti-IL-6 receptor antibody
  DISEASE   Neuromyelitis optica spectrum disorder (anti-AQP4 antibody positive) [DS:H01491]
  TYPE      Monoclonal antibody
COMMENT     Treatment of neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorders (NMO-SD)
TARGET      IL6R (CD126) [HSA:3570] [KO:K05055]
  PATHWAY   hsa04060(3570)  Cytokine-cytokine receptor interaction
            hsa04630(3570)  JAK-STAT signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AC Interleukin inhibitors
                 L04AC19 Satralizumab
                  D11079  Satralizumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Ophthalmic Agents
              Ophthalmic Agents, Other
               Ophthalmic Agents, Monoclonal Antibodies
                Satralizumab
                 D11079  Satralizumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              63  Biological preparations
               639  Miscellaneous
                6399  Others
                 D11079  Satralizumab (USAN/INN); Satralizumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D11079  Satralizumab
            Drug classes [BR:br08332]
             Immunological agent
              DG02019  Interleukin inhibitor
               D11079  Satralizumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               Interleukin receptors
                IL6R (CD126)
                 D11079  Satralizumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11079
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11079
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11079
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11079
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D11079
DBLINKS     CAS: 1535963-91-7
            PubChem: 375581026
///
